Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1129)	6/21/2005 12:43:00 PM
From: Jibacoa	Respond to of 3722

LEXG Is trying to get over the resistance at the $5 level. It has to do that before it can test its May 24 H at 5.20 <g> The stock has shown support at the 4.25 level and started on a nearterm uptrend on June 15 from the 4.35 level. The March Q results were better compared to previous year with revenues up 18% to 13.9M and the loss $0.21/shr vs. $0.25/shr but the EL for 2005 is a little more than in 2004 at $0.78/shr and for 2006 the EL is around $0.88/shr. LEXG announced today a collaboration with XOMA to develop antibody drugs for targets discovered by LEXG. bigcharts.marketwatch.com The longer term chart on LEXG remains interesting.<g> bigcharts.marketwatch.com Bernard